ABBOTT LABORATORIES vs NOVO NORDISK A/S, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Neither growth rate appears on this page, but the multiples have already voted: Novo Nordisk at 14.2 times earnings is priced as if its GLP-1 franchise has finished growing, Abbott at 26.3 times as if its diversified devices-and-nutrition estate never will. The income statements make the discount stranger: Novo keeps 41.3 cents of each revenue dollar as operating profit against Abbott's 12.1, earns 52.8% on equity against 11.9%, and both convert similar slices of price into free cash, near 4-4.5%. Abbott pays the visible 2.6% dividend. A margin machine at nearly half the multiple of a steady conglomerate is the market pricing one specific fear, competitive erosion in obesity drugs, at more than the whole rest of the franchise.
Comparison updated 2026-07-10.
| Metric | ABT | NVO |
|---|---|---|
| Price | $93.86 | $48.01 |
| Market cap | $164.0B | $213.3B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Growth |
| Implied growth (priced in) | +8.8% | — |
| P/E | 26.3 | 14.2 |
| P/B | 3.11 | 7.47 |
| P/S | 3.63 | 4.69 |
| EV/EBITDA | 20.8 | 10.0 |
| Revenue growth | +6.6% | +22.1% |
| Gross margin | — | 81.0% |
| Operating margin | 12.1% | 41.3% |
| Net margin | 13.9% | 33.1% |
| Return on equity | 11.9% | 52.8% |
| Return on assets | 5.7% | 18.9% |
| Return on invested capital | 6.6% | 51.6% |
| FCF yield | 4.5% | 4.1% |
| Dividend yield | 2.6% | — |
| Debt / equity | 0.65 | 0.00 |
| Current ratio | 1.39 | 0.80 |
| Altman Z (solvency) | 7.16 | 4.25 |
| Piotroski F (quality) | 6 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.